We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AstraZeneca/Merck's Lynparza Betters Survival in Phase III
Read MoreHide Full Article
AstraZeneca (AZN - Free Report) and Merck’s (MRK - Free Report) cancer tablet, Lynparza demonstrated significant delay in disease progression in a late-stage study evaluating it for the first-line treatment of advanced ovarian cancer.
The phase III SOLO-1 study (n=391) met the primary endpoint demonstrating that first-line treatment with Lynparza maintenance therapy led to a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) compared to placebo in women with BRCA-mutated (BRCAm) advanced ovarian cancer. Meanwhile, the PARP inhibitor demonstrated a well-characterized safety and tolerability profile in the study.
Full data from the SOLO-1 study will be presented at a future medical meeting. The companies plan to conduct discussions related to submissions to get Lynparza approved in the first-line maintenance setting with regulatory authorities. If approved for expanded use in the first-line setting, sales of Lynparza can improve in the future quarters.
Lynparza is presently marketed for advanced ovarian cancer in later settings. In January, Lynparza became the first PARP-inhibitor to be approved for a breast cancer indication in the United States. Lynparza is also in different studies for a range of tumor types including breast, prostate and pancreatic cancers as well as earlier-line settings for ovarian cancer.
In the first quarter of 2018, Lynparza sales rose 100% to $119 million. Sales in the United States surged 144%, gaining from recent label expansion approvals in ovarian cancer, tablets, and breast cancer indication. In Europe, sales rose 44%, pushed higher by a number of successful launches, high BRCA-testing rates and encouraging levels of reimbursement.
Clovis Oncology, Inc.’s Rubraca and Tesaro, Inc.’s Zejula are the other PARP inhibitors, which pose competition for Lynparza in the United States.
AstraZeneca’s shares have risen 0.5% so far this year while Merck’s stock is up 7.9%. In contrast, the industry has declined 4.9%.
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce ""the world's first trillionaires,"" but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
AstraZeneca/Merck's Lynparza Betters Survival in Phase III
AstraZeneca (AZN - Free Report) and Merck’s (MRK - Free Report) cancer tablet, Lynparza demonstrated significant delay in disease progression in a late-stage study evaluating it for the first-line treatment of advanced ovarian cancer.
The phase III SOLO-1 study (n=391) met the primary endpoint demonstrating that first-line treatment with Lynparza maintenance therapy led to a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) compared to placebo in women with BRCA-mutated (BRCAm) advanced ovarian cancer. Meanwhile, the PARP inhibitor demonstrated a well-characterized safety and tolerability profile in the study.
Full data from the SOLO-1 study will be presented at a future medical meeting. The companies plan to conduct discussions related to submissions to get Lynparza approved in the first-line maintenance setting with regulatory authorities. If approved for expanded use in the first-line setting, sales of Lynparza can improve in the future quarters.
Lynparza is presently marketed for advanced ovarian cancer in later settings. In January, Lynparza became the first PARP-inhibitor to be approved for a breast cancer indication in the United States. Lynparza is also in different studies for a range of tumor types including breast, prostate and pancreatic cancers as well as earlier-line settings for ovarian cancer.
In the first quarter of 2018, Lynparza sales rose 100% to $119 million. Sales in the United States surged 144%, gaining from recent label expansion approvals in ovarian cancer, tablets, and breast cancer indication. In Europe, sales rose 44%, pushed higher by a number of successful launches, high BRCA-testing rates and encouraging levels of reimbursement.
Clovis Oncology, Inc.’s Rubraca and Tesaro, Inc.’s Zejula are the other PARP inhibitors, which pose competition for Lynparza in the United States.
AstraZeneca’s shares have risen 0.5% so far this year while Merck’s stock is up 7.9%. In contrast, the industry has declined 4.9%.
Both AstraZeneca and Merck have a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce ""the world's first trillionaires,"" but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>